Selinexor (KPT-330) is primarily used in the treatment of certain types of cancer. It is specifically approved for use in patients with relapsed or refractory multiple myeloma, particularly in combination with dexamethasone. The drug works by inhibiting the exportin 1 (XPO1) protein, which is involved in the transport of tumor suppressor proteins out of the nucleus. By blocking XPO1, Selinexor helps to retain these proteins in the nucleus, thereby promoting cancer cell death.

In addition to multiple myeloma, Selinexor is being investigated for its potential efficacy in other hematologic malignancies and solid tumors. Clinical trials are ongoing to explore its use in conditions such as diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), and various forms of sarcoma. The drug is administered orally, making it a convenient option for patients who require long-term treatment.

Despite its promising therapeutic benefits, Selinexor is associated with several side effects, including nausea, fatigue, and thrombocytopenia. Management of these side effects is crucial for maintaining patient quality of life during treatment. Overall, Selinexor represents a novel therapeutic approach in oncology, offering hope for patients with limited treatment options.